Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 7/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11406620 | 0.84 | SRC (0.40) | SMN1; SMN2SRCALDH1A1IDO1MEN1 | |
| SCHEMBL5539864 | 0.80 | FDPS (0.36) | FDPSCYP3A4ALOX15CASP1CASP7 | |
| Ethoxycarbonyl Group SCHEMBL28870102 | 0.80 | ALDH1A1 (0.42) | FDPSCYP3A4ALOX15CASP1CASP7 | |
| SCHEMBL27671951 | 0.79 | KDM4E (0.49) | SMN1; SMN2SRCIDO1 | |
| SCHEMBL11809567 | 0.79 | ALDH1A1 (0.37) | FDPSCYP3A4ALOX15CASP1CASP7 | |
| Propylformate SCHEMBL28281240 | 0.77 | CYP1A2 (0.41) | FDPSALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL5984182 | 0.77 | SRC (0.42) | SRCIDO1L3MBTL1 | |
| SCHEMBL133172 | 0.75 | CDK4 (0.50) | SRCALDH1A1TSHRKMT2A | |
| SCHEMBL28924 | 0.75 | IDO1 (0.55) | SMN1; SMN2ALDH1A1HSD17B10TSHRIDO1 | |
| SCHEMBL98043 | 0.75 | IDO1 (0.55) | ALDH1A1IDO1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116806157-A | Linker-payload and conjugates thereof | 芬兰吉利科斯有限公司 | 2023-09-26 | — | — | CN | claimed |
| CN-111065416-A | Hydrophilic linkers and conjugates thereof | 芬兰吉利科斯有限公司 | 2020-04-24 | — | — | CN | claimed |
| EP-4267188-A1 | COMPOUNDS COMPRISING A TETRAPEPTIDIC MOIETY | Cobiores NV (BE) | 2023-11-01 | — | — | EP | disclosed |
| CN-116806157-A | Linker-payload and conjugates thereof | 芬兰吉利科斯有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-116635054-A | Compounds comprising tetrapeptide moieties | 科比欧尔斯公司 | 2023-08-22 | — | — | CN | disclosed |
| WO-2022167664-A1 | COMPOUNDS COMPRISING A TETRAPEPTIDIC MOIETY | COBIORES NV (BE) | 2022-08-11 | — | — | WO | disclosed |
| WO-2022136586-A1 | COMPOUNDS COMPRISING A TETRAPEPTIDIC MOIETY | COBIORES NV (BE) | 2022-06-30 | — | — | WO | disclosed |
| CN-106749665-B | Conjugates of CC-1065 analogs and bifunctional linkers | 辛塔佳有限公司 | 2021-03-26 | — | — | CN | disclosed |
| CN-111065416-A | Hydrophilic linkers and conjugates thereof | 芬兰吉利科斯有限公司 | 2020-04-24 | — | — | CN | disclosed |
| EP-2405944-B1 | PRODRUGS | KTB TUMORFORSCHUNGS GMBH (DE) | 2016-01-27 | — | — | EP | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| US-8642555-B2 | Prodrugs | KTB TUMORFORSCHUNGSGESELLSCHAFT MBH (DE) | 2014-02-04 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20120094892-A1 | PRODRUGS | KTB TUMORFORSCHUNGSGESELLSCHAFT MBH (DE) | 2012-04-19 | — | — | US | disclosed |
| EP-2405944-A1 | PRODRUGS | KTB Tumorforschungsgesellschaft mbH (DE) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010102788-A1 | PRODRUGS | KTB TUMORFORSCHUNGSGESELLSCHAFT MBH (DE) | 2010-09-16 | — | — | WO | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | FDPS 1781/4885CYP3A4 1683/4885ALOX15 2847/4885 |
| US-20120094892-A1 | PRODRUGS | ACP3, KLK3, FOLH1 | FDPS 261/4885CYP3A4 646/4885ALOX15 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.